Table 1 Summary of results of potential makers validated using a targeted proteomic mass spectrometry test
Alzheimer’s disease | Lewy body dementia | Parkinson’s disease | |||
|---|---|---|---|---|---|
Protein biomarker | Fold-change (statistical significance) | Protein biomarker | Fold-change (statistical significance) | Protein biomarker | Fold-change (statistical significance) |
Osteopontin | 4.7 (p < 0.002) |  |  | DJ1 | 3.1 (p < 0.0053) |
|  |  | Osteopontin | 2.3 (p < 0.02) | aMalate dehydrogenase | 2.2 (not significant) |
CNDP1 | 3.2 (p < 0.0001) | aUCHL1 | 2.2 (p < 0.01) | aLSAMP | 1.9 (p < 0.0136) |
aMalate dehydrogenase | 3.2 (p < 0.0001) | Chitinase-3-like protein 1 | 2.1 (p < 0.0004) | Apolipoprotein H | 1.8 (p < 0.0484) |
Apolipoprotein E | 2.9 (p < 0.0001) | aGM2 Activator Protein | 1.9 (p < 0.0087) | Serum Amyloid A4 | 1.7 (not significant) |
Ubiquitin | 2.3 (p < 0.0015) | aMalate dehydrogenase | 1.9 (p < 0.0082) | Pro-orexin | 1.6 (not significant) |
aGM2 Activator Protein | 2.3 (p < 0.0002) | aSerum Amyloid A4 | 1.9 (p < 0.0092) | Osteopontin | 1.6 (p < 0.02) |
IBP2 | 2.3 (p < 0.0001) | Apolipoprotein E | 1.7 (p < 0.0014) | UCHL1 | 1.5 (not significant) |
aSerum Amyloid A4 | 2.3 (p < 0.0007) | CNDP1 | 1.7 (p < 0.0039) | Prosaposin | 1.5 (not significant) |
aPro-orexin | 2.2 (p < 0.0017) | Apolipoprotein H | 1.7 (p < 0.01) | Vitamin D binding protein | 1.5 (p = 0.05) |
aCarboxypeptidase E | 2.2 (p < 0.0001) | aProsaposin | 1.7 (p < 0.02) | Chitinase-3-like protein 1 | 1.4 (not significant) |
Apolipoprotein H | 2.2 (p < 0.0001) | S100B | 1.7 (p < 0.031) | GM2 Activator Protein | 1.3 (not significant) |
Chitinase-3-like protein 1 | 2.2 (p < 0.0012) | Ubiquitin | 1.6 (p < 0.011) | S100B | 1.3 (not significant) |
aprosaposin | 2.1 (p < 0.0001) | Insulin-like growth factor 2 | 1.6 (p < 0.0052) | Apolipoprotein E | 1.2 (not significant) |
aUCHL1 | 2 (p < 0.0108) | Cystatin C | 1.6 (p < 0.002) | CNDP1 | 1.2 (not significant) |
aLAMP1 | 2 (p < 0.0003) | Vitamin D binding protein | 1.6 (p < 0.01) | Clusterin | 1.2 (not significant) |
Cystatin C | 1.9 (p < 0.0001) | IBP2 | 1.6 (p < 0.0052) | Cystatin C | 1.2 (not significant) |
Vitamin D binding protein | 1.9 (p < 0.0001) | LAMP1 | 1.5 (not significant) | Transferrin | 1.2 (not significant) |
Transthyretin | 1.8 (p < 0.0001) | aCarboxypeptidase E | 1.5 (p < 0.0097) | LAMP1 | 1.1 (not significant) |
Insulin-like growth factor 2 | 1.8 (p < 0.0015) | aTREM 2 | 1.5 (p < 0.0062) | Carboxypeptidase E | 1.1 (not significant) |
aTREM 2 | 1.8 (p < 0.0003) | aLSAMP | 1.5 (p < 0.0004) | TIMP1 | 1.1 (not significant) |
aLSAMP | 1.8 (0.0009) | Pro-orexin | 1.4 (not significant) | Insulin-like growth factor 2 | 1.1 (not significant) |
ENPP2 | a1.7 (p < 0.0001) | Clusterin | 1.4 (p < 0.0102) | TREM 2 | 1.1 (not significant) |
S100B | 1.7 (p < 0.0037) | TIMP1 | 1.4 (p < 0.0055) | IBP2 | 1.1 (not significant) |
Clusterin | 1.6 (p < 0.0001) | Transferrin | 1.4 (p < 0.01) | Transthyretin | 1 (not significant) |
Transferrin | 1.4 (p < 0.0015) | Transthyretin | 1.1 (not significant) | Ubiquitin | 0.9 (not significant) |
TIMP1 | 1.3 (p < 0.018) | ENPP2 | 1 (not significant) | ENPP2 | 0.8 (not significant) |